Target intelligence / Profile preview

3-O-sulfated heparan sulfate (3-OS HS)

Target
3-OS HS
Molecular classification
Glycosaminoglycan, Polysaccharide, Receptor, Co-receptor
01

Overview

3-O-sulfated heparan sulfate (3-OS HS) is a rare but biologically critical modification of heparan sulfate, a linear polysaccharide found on cell surfaces and in the extracellular matrix [1.1.3, 1.2.3]. This specific sulfation at the 3-OH position of glucosamine residues is catalyzed by a family of 3-O-sulfotransferase (HS3ST) enzymes and creates unique binding motifs for various effector proteins [1.3.1, 1.4.1]. One of its most well-characterized roles is in the anticoagulation cascade, where a specific 3-OS HS pentasaccharide sequence binds and activates antithrombin III to inhibit clotting factors like Factor Xa [1.1.2, 1.4.3]. Beyond its role in blood homeostasis, 3-OS HS serves as a critical entry receptor for Herpes Simplex Virus 1 (HSV-1) by interacting with the viral envelope glycoprotein D [1.3.2, 1.3.4]. Recent studies have also linked 3-OS HS to neurodegenerative conditions, particularly Alzheimer's disease, where it facilitates the cellular uptake and spread of tau protein [1.2.1, 1.2.4]. Consequently, 3-OS HS is a key therapeutic target, with drugs like fondaparinux mimicking its structure for anticoagulation and ongoing research exploring its inhibition to treat viral infections and dementia [1.4.2, 1.4.3].

Other names
3-O-sulfated HS3-O-S HS3-OST-modified heparan sulfateAnticoagulant heparan sulfate3-O-sulfated glucosamine-containing heparan sulfate
02

Mechanism of action

3-O-sulfated heparan sulfate acts as a critical binding site for antithrombin III, inducing a conformational change that accelerates the inhibition of Factor Xa and thrombin [1.1.2, 1.4.3]. In viral pathogenesis, it serves as a specific receptor for the Herpes Simplex Virus 1 (HSV-1) glycoprotein D, facilitating viral-host membrane fusion and entry [1.3.1, 1.3.2]. Additionally, it interacts with tau protein and ApoE in the brain, promoting the cellular uptake and aggregation of tau in neurodegenerative pathways [1.2.1, 1.2.2].

03

Biological functions

AnticoagulationViral entrySignal transductionCell signalingOther
04

Disease associations

InfectionCardiovascular diseaseNeurodegenerative diseaseCancerInflammation
05

Safety considerations

Hemorrhage and bleeding riskHeparin-induced thrombocytopenia (HIT)Altered susceptibility to viral infections
06

Interacting drugs

Heparin

6 more in the full profile.

07

Biomarkers

3-O-sulfated heparan sulfate brain levelsHS3ST1 genetic polymorphismsCirculating heparan sulfate fragments

Beyond the preview

Go deeper on 3-O-sulfated heparan sulfate (3-OS HS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-O-sulfated heparan sulfate (3-OS HS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call